These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11362352)

  • 1. Una conferencia de amnesia.
    Haas GJ
    Common Factor; 1995 Apr; (no 10):30. PubMed ID: 11362352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemophilia and HTLV-III infection].
    Lechler E
    Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defendants challenge class action certification.
    Dubin CS; Wadleigh J
    Common Factor; 1995 Apr; (no 10):1, 33-36. PubMed ID: 11362336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Academy of Sciences convenes public hearing on HIV and the blood supply.
    Dubin CS
    Common Factor; 1995 Apr; (no 10):4. PubMed ID: 11362355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status and future prospects of hemophilia treatment].
    Lopaciuk S
    Acta Haematol Pol; 1995; 26(2 Suppl 1):44-55. PubMed ID: 7653234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIV-1 infection on CD4 cells in a hemophilia cohort.
    Green D; Deutsche J; Tang M; Goldsmith J
    Haematologica; 1990; 75 Suppl 5():132-41. PubMed ID: 1982277
    [No Abstract]   [Full Text] [Related]  

  • 11. Dallas, police surveillance and the NHF. National Hemophilia Foundation.
    Dubin CS
    Common Factor; 1995 Apr; (no 10):3, 31-2. PubMed ID: 11362351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemophilia A.
    Lusher JM; Warrier I
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1021-33. PubMed ID: 1400070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia--an ancient disease with new problems and new solutions.
    Rogers JS; Ritchey AK
    W V Med J; 1992 Feb; 88(2):50-3. PubMed ID: 1557907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHO, pharmaceutical industry unite against AIDS.
    Glob AIDSnews; 1992; (1):7. PubMed ID: 12285124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Makers of clotting medicine not entitled to liability shield.
    AIDS Policy Law; 1996 Feb; 11(3):7. PubMed ID: 11363179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia relief fund.
    Body Posit; 1998 Dec; 11(12):15. PubMed ID: 11366136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The good, the bad & the ugly: the political economy of the blood products industry.
    Dubin CS
    Common Factor; 1998 Oct; (No 12):4-5, 8. PubMed ID: 11365880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in care of children with hemophilia.
    Manco-Johnson MJ; Riske B; Kasper CK
    Semin Thromb Hemost; 2003 Dec; 29(6):585-94. PubMed ID: 14719175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor products in the treatment of hemophilia.
    Miller KL
    J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemophilia replacement therapy in developing countries: complementary approaches to the question of indigenous product manufacture versus importation.
    Gellert GA
    Thromb Haemost; 1996 Feb; 75(2):373-4. PubMed ID: 8815594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.